1. Transglutaminase 2 and NF-κB: an odd couple that shapes breast cancer phenotype

   • Kevin D. Brown

   Review 08 December 2012 Pages: 329 - 336

   

2. Is mammographic density differentially associated with breast cancer according to receptor status? A meta-analysis

   • Sebastien Antoni
   • Annie J. Sasco
   • Valerie McCormack

   Review 13 December 2012 Pages: 337 - 347

   

3. Trastuzumab administration during pregnancy: a systematic review and meta-analysis

   • Flora Zagouri
   • Theodoros N. Sergentanis
   • Rupert Bartsch

   Review 15 December 2012 Pages: 349 - 357

   

4. Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-α-independent mechanism

   • Jennifer L. Allensworth
   • Scott J. Sauer
   • Gayathri R. Devi

   Preclinical Study 07 December 2012 Pages: 359 - 371

   

5. MicroRNA-30c targets cytoskeleton genes involved in breast cancer cell invasion

   • Jessica Bockhorn
   • Kathy Yee
   • Huiping Liu

   Preclinical study 07 December 2012 Pages: 373 - 382

   

6. Vimentin DNA methylation predicts survival in breast cancer

   • Jacob Ulirsch
   • Cheng Fan
   • Theresa Swift-Scanlan

   Preclinical study 13 December 2012 Pages: 383 - 396

   

7. Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit

   • Josefine Bostner
   • Elin Karlsson
   • Olle Stål

   Preclinical Study Open access 15 December 2012 Pages: 397 - 406

   

8. Prognostic evaluation of the B cell/IL-8 metagene in different intrinsic breast cancer subtypes

   • Lars C. Hanker
   • Achim Rody
   • Thomas Karn

   Preclinical Study 16 December 2012 Pages: 407 - 416

   

9. Differential expression of immune-related markers in breast cancer by molecular phenotypes

   • Junjeong Choi
   • Do Hee Kim
   • Ja Seung Koo

   Preclinical Study 16 December 2012 Pages: 417 - 429

   

10. Estrogen switches pure mucinous breast cancer to invasive lobular carcinoma with mucinous features

    • Purevsuren Jambal
    • Melanie M. Badtke
    • Britta M. Jacobsen

    Preclinical Study 18 December 2012 Pages: 431 - 448

    

11. Effect of HER2 status on distant recurrence in early stage breast cancer

    • Kenneth R. Hess
    • Francisco J. Esteva

    Clinical trial 06 December 2012 Pages: 449 - 455

    

12. Phase II study evaluating lapatinib in combination with nab-paclitaxel in HER2-overexpressing metastatic breast cancer patients who have received no more than one prior chemotherapeutic regimen

    • Denise A. Yardley
    • Lowell Hart
    • Yasir Nagarwala

    Clinical Trial Open access 08 December 2012 Pages: 457 - 464

13. Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients

    • Holm Eggemann
    • Atanas Ignatov
    • Serban-Dan Costa

    Clinical trial 09 December 2012 Pages: 465 - 470

    

14. A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer

    • Massimo Cristofanilli
    • Stephen R. D. Johnston
    • Maureen E. Trudeau

    Clinical Trial Open access 13 December 2012 Pages: 471 - 482

    

15. A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer

    • Cynthia X. Ma
    • Matthew J. C. Ellis
    • Paula M. Fracasso

    Clinical trial Open access 15 December 2012 Pages: 483 - 492

    

16. Alterations in brain structure and function in breast cancer survivors: effect of post-chemotherapy interval and relation to oxidative DNA damage

    • Susan K. Conroy
    • Brenna C. McDonald
    • Andrew J. Saykin

    Clinical Trial 22 December 2012 Pages: 493 - 502

    

17. The prognostic impact of circulating tumor cells in subtypes of metastatic breast cancer

    • Markus Wallwiener
    • Andreas Daniel Hartkopf
    • Tanja Natascha Fehm

    Clinical trial 28 December 2012 Pages: 503 - 510

    

18. Assessing interactions between the associations of fibroblast growth factor receptor 2 common genetic variants and hormone receptor status with breast cancer risk

    • Hong Wang
    • Ziang Yang
    • Hongwei Zhang

    Epidemiology 27 November 2012 Pages: 511 - 522

    

19. Adding hormonal therapy to chemotherapy and trastuzumab improves prognosis in patients with hormone receptor-positive and human epidermal growth factor receptor 2-positive primary breast cancer

    • Naoki Hayashi
    • Naoki Niikura
    • Naoto T. Ueno

    Epidemiology 27 November 2012 Pages: 523 - 531

    

20. Nonsense mutation p.Q548X in BLM, the gene mutated in Bloom’s syndrome, is associated with breast cancer in Slavic populations

    • Darya Prokofyeva
    • Natalia Bogdanova
    • Thilo Dörk

    Epidemiology 06 December 2012 Pages: 533 - 539

21. Total energy intake and breast cancer risk in sisters: the Breast Cancer Family Registry

    • Fang Fang Zhang
    • Esther M. John
    • Mary Beth Terry

    Epidemiology 06 December 2012 Pages: 541 - 551

22. Association between BRIP1 (BACH1) polymorphisms and breast cancer risk: a meta-analysis

    • Noel Pabalan
    • Hamdi Jarjanazi
    • Hilmi Ozcelik

    Epidemiology 06 December 2012 Pages: 553 - 558

    

23. Genetic variants in FGFR2 and MAP3K1 are associated with the risk of familial and early-onset breast cancer in a South-American population

    • Lilian Jara
    • Patricio Gonzalez-Hormazabal
    • Gigia Roizen

    Epidemiology 07 December 2012 Pages: 559 - 569

24. Impact of breast cancer on anti-mullerian hormone levels in young women

    • H. I. Su
    • S. W. Flatt
    • A. Z. Steiner

    Epidemiology 09 December 2012 Pages: 571 - 577

    

25. Reproductive factors and risk of estrogen receptor positive, triple-negative, and HER2-neu overexpressing breast cancer among women 20–44 years of age

    • Christopher I. Li
    • Elisabeth F. Beaber
    • Kathleen E. Malone

    Epidemiology 09 December 2012 Pages: 579 - 587

26. Mind the gap: racial differences in breast cancer incidence and biologic phenotype, but not stage, among low-income women participating in a government-funded screening program

    • Joan E. Cunningham
    • Christine A. Walters
    • Charles L. Bennett

    Epidemiology 13 December 2012 Pages: 589 - 598

    

27. Association between 25-hydroxyvitamin D concentration and breast cancer risk in an Australian population: an observational case–control study

    • K. Bilinski
    • J. Boyages

    Epidemiology 14 December 2012 Pages: 599 - 607

28. One-day core needle biopsy in a breast clinic: 4 years experience

    • Joris P. Bulte
    • Lenny Polman
    • Johannes H. W. De Wilt

    Epidemiology 14 December 2012 Pages: 609 - 616

    

29. Pain in long-term breast cancer survivors: the role of body mass index, physical activity, and sedentary behavior

    • Laura P. Forsythe
    • Catherine M. Alfano
    • Rachel Ballard-Barbash

    Epidemiology 15 December 2012 Pages: 617 - 630

    

30. Elevated serum P1NP predicts development of bone metastasis and survival in early-stage breast cancer

    • Windy Dean-Colomb
    • Kenneth R. Hess
    • Francisco J. Esteva

    Epidemiology 15 December 2012 Pages: 631 - 636

    

31. PTP1B expression is an independent positive prognostic factor in human breast cancer

    • S. Soysal
    • E. C. Obermann
    • S. Muenst

    Epidemiology 16 December 2012 Pages: 637 - 644

    

32. Unincluded subjects need to be included for concerning the real association between TNFa−308 G/A polymorphism and cancer susceptibility

    • Guoqiang Zhang
    • Zengyan Liu
    • Zhenlin Yang

    Letter to the Editor 27 November 2012 Pages: 645 - 646

33. Comments on the use of a single or multiple probe-set approach for microarray-based analyses of routine molecular markers in breast cancer

    • Danila Coradini
    • Federico Ambrogi
    • Patrizia Boracchi

    Letter To the Editor 19 December 2012 Pages: 647 - 651